Physician profile
Rajkumar K Sugumaran
NPI 1184840506
$957,253.10
in general payments reported to CMS, 2019-2025
55 companies · $208K in 2025
The $208K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $64K · 2021: $80K · 2022: $137K · 2023: $167K · 2024: $196K · 2025: $208K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $456K · Travel and Lodging: $57K · Food and Beverage: $25K · Long Term Medical Supply Or Device Loan: $20K · Consulting Fee: $11K · Charitable Contribution: $1,615 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $456,327.94 |
| Travel and Lodging | $57,255.44 |
| Food and Beverage | $24,881.98 |
| Long Term Medical Supply Or Device Loan | $19,916.67 |
| Consulting Fee | $11,310.00 |
| Charitable Contribution | $1,614.62 |
| Education | $112.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $319,407.38 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160,463.70 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $137,719.88 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $119,891.06 | 2022-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $63,780.38 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46,656.94 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $42,380.32 | 2019-2025 | Watchman Access System, Watchman Flx, General - Therapies |
| Angiodynamics, INC. | $20,032.75 | 2022-2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Bayer Healthcare Pharmaceuticals INC. | $10,736.07 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $8,877.40 | 2021-2025 | Verquvo, Capvaxive |
| Terumo Medical Corporation | $7,425.50 | 2019-2022 | |
| Abbott Laboratories | $2,833.00 | 2019-2025 | Cardiomems, Gallant, Perclose Prostyle |
| Corcept Therapeutics | $2,580.45 | 2023-2025 | Korlym |
| Itamar Medical INC | $1,874.42 | 2022-2024 | Watchpatone |
| Philips North America LLC | $1,863.87 | 2020-2025 | Coronary Other, Coronary Undivided, Encore |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,627.38 | 2019-2020 | |
| Zoll Circulation INC | $1,273.05 | 2023-2024 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Abiomed | $955.24 | 2019-2025 | Impella |
| Medtronic, INC. | $939.97 | 2021-2024 | Micra, Azure Xt Dr Mri Surescan, Resolute Onyx |
| Astrazeneca Pharmaceuticals Lp | $913.06 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $680.55 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $509.31 | 2024-2025 | Assure Wcd |
| Heartflow, INC. | $403.16 | 2023 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $348.31 | 2023-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $329.34 | 2021-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $322.36 | 2019-2024 | Opsumit, Uptravi |
| Chiesi USA, INC. | $253.06 | 2020-2025 | Juxtapid |
| Edwards Lifesciences Corporation | $233.27 | 2020-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bardy Diagnostics, INC. | $180.00 | 2021-2022 | |
| Astellas Pharma US INC | $175.95 | 2020-2021 | |
| Cleerly, INC. | $165.87 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Pfizer INC. | $163.15 | 2022-2025 | |
| Amarin Pharma, INC. | $152.83 | 2020-2021 | |
| Baxter Healthcare | $111.22 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $109.41 | 2022-2025 | Amvuttra |
| Biosense Webster, INC. | $102.42 | 2024 | Carto 3 |
| Cvrx, INC. | $95.40 | 2020-2023 | Barostim Neo System |
| Daiichi Sankyo INC. | $95.27 | 2023 | Injectafer |
| Atricure, INC. | $74.28 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $69.88 | 2019-2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $51.91 | 2024 | Arcalyst |
| Zoll Respicardia, INC. | $46.49 | 2023-2024 | Remede System |
| Inspire Medical Systems, INC. | $46.11 | 2025 | Inspire |
| Stryker Corporation | $45.99 | 2023-2025 | Clottriever Bold Catheter, Scopis Ent |
| Glaxosmithkline, LLC. | $35.14 | 2023 | Nucala |
| Penumbra, INC. | $34.58 | 2025 | Indigo System |
| Sanofi-Aventis U.S. LLC | $29.42 | 2020-2024 | |
| Cook Medical LLC | $29.39 | 2021 | |
| Ekos Corporation | $22.76 | 2019 | |
| Endologix LLC | $20.77 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $19.37 | 2024 | |
| Impulse Dynamics (USA) INC. | $18.41 | 2022 | |
| Teleflex LLC | $17.45 | 2025 | Quikclot |
| Preventice Services, LLC | $14.29 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $14.16 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,795.63 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajkumar Sugumaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.